Furthermore, several preclinical studies in cell lines and xenograft models of bladder cancer have shown that FGFR3 alterations confer sensitivity to FGFR inhibitors, which have anti‐proliferative and pro‐apoptotic effects (Bernard‐Pierrot et al, 2006; Wu et al, 2013; Nakanishi et al, 2015). This evidence concerns the gene FGFR3 and urinary bladder cancer.